LL-37

LL-37 is the only human cathelicidin antimicrobial peptide, a 37-amino acid cationic peptide derived from hCAP18 that exhibits broad-spectrum antimicrobial activity against bacteria, viruses, and fungi while modulating immune responses and promoting wound healing.

• Chronic Venous Leg Ulcers
• Diabetic Foot Ulcers
• Pressure Ulcers

Systemic immune support, broad-spectrum antimicrobial activity, enhanced wound healing from within

Subcutaneous administration provides systemic distribution for immune modulation and antimicrobial support throughout the body

Peak plasma concentration: 3 min. Elimination half-life: 30 min. Largely cleared by: ~2.5 hrs.

Research protocols from published literature — not dosing recommendations.

• BPC-157 — Synergistic: Enhanced wound healing and tissue repair through complementary mechanisms - LL-37 provides antimicrobial protection while BPC-157 accelerates tissue regeneration.
• TB-500 — Synergistic: Combined anti-inflammatory and healing effects with LL-37 providing antimicrobial activity and TB-500 enhancing cellular migration and angiogenesis.
• Conventional Antibiotics — Synergistic: LL-37 demonstrates synergistic effects with chloramphenicol, ciprofloxacin, and oxacillin against multidrug-resistant bacteria, with FICI values 0.25-0.5.
• Vitamin D3 — Synergistic: Vitamin D3 acts as cofactor for VDR to induce endogenous LL-37 production, enhancing innate immune responses and antimicrobial activity.
• Lactoferrin — Compatible: Both antimicrobial peptides can be used together safely with no documented negative interactions in wound healing applications.
• Physiological Salt Solutions — Use Caution: High salt concentrations in physiological environments can reduce LL-37 antimicrobial activity. Consider dosing adjustments in high-salt conditions.
• Amino Acid Solutions — Avoid Combination: Physical incompatibility may occur with certain amino acid solutions, particularly in IV formulations. Avoid co-administration in same solution.
• Novel Synthetic AMPs — Unknown: Limited data on interactions with other synthetic antimicrobial peptides. Clinical interaction profile not established for most combinations.

Supplies:

• LL-37 lyophilized peptide (1-5 mg vials)
• Bacteriostatic water for injection
• Sterile syringes and needles
• Alcohol swabs for injection site preparation

1. 1Allow LL-37 vial to reach room temperature before reconstitution
2. 2Add appropriate volume of bacteriostatic water slowly to peptide vial
3. 3Gently swirl or roll vial to dissolve - do not shake vigorously
4. 4Calculate dose based on final concentration (typically 1-2 mg/mL)
5. 5Use sterile technique for injection preparation
6. 6Inject subcutaneously in abdomen, thigh, or upper arm areas
7. 7Rotate injection sites to prevent tissue irritation

Week 1-2: Initial immune system modulation, possible mild injection site reactions. Week 2-4: Enhanced antimicrobial activity, improved wound healing if applicable. Week 4-8: Sustained immune support, optimized inflammatory responses. Week 8-12: Maximum benefits for chronic applications, established immune enhancement.

Monitor injection sites for excessive irritation or inflammatory reactions. Start with lower doses (50-100 mcg) to assess individual tolerance. Discontinue if signs of hypersensitivity or allergic reactions develop. Use proper sterile injection technique to prevent contamination.

Monitor injection sites for excessive irritation or inflammatory reactions. Start with lower doses (50-100 mcg) to assess individual tolerance. Discontinue if signs of hypersensitivity or allergic reactions develop. Use proper sterile injection technique to prevent contamination.

LL-37 should be stored at Refrigerate 2-8°C after reconstitution, use within 30 days.